Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21760453 | 0.82 | ALDH1A1 (0.54) | TSHRALDH1A1MAPK1L3MBTL1GLA | |
| SCHEMBL3490697 | 0.80 | ALDH1A1 (0.45) | GSK3AGSK3BALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL31421039 | 0.78 | GAA (0.55) | GSK3AGSK3BL3MBTL1KMT2A | |
| SCHEMBL23298275 | 0.77 | GSK3A (0.57) | GSK3AGSK3BALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL20083679 | 0.76 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1KMT2A | |
| SCHEMBL25426510 | 0.76 | ALDH1A1 (0.54) | TSHRALDH1A1MAPK1L3MBTL1GLA | |
| SCHEMBL8062425 | 0.76 | GSK3A (0.63) | GSK3AGSK3BTSHRALDH1A1MAPK1 | |
| SCHEMBL14374083 | 0.76 | MAPK1 (0.43) | ALDH1A1MAPK1L3MBTL1GLACYP1A2 | |
| SCHEMBL16223202 | 0.75 | TSHR (0.58) | GSK3AGSK3BTSHRALDH1A1KMT2A | |
| SCHEMBL15157067 | 0.75 | NOTUM (0.52) | ALDH1A1MAPK1L3MBTL1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1313730-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018378-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | CMA1, CTRL, TPSD1 | GSK3A 4662/4885GSK3B 4510/4885TSHR 2174/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | GSK3A 1637/4885GSK3B 1705/4885TSHR 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.